Sermorelin: a growth hormone-releasing peptide and its regulatory status
Sermorelin is a short synthetic version of growth hormone-releasing hormone. It was once sold in the United States as Geref, to test for growth hormone deficiency and to treat children who were not growing. That product is no longer marketed. Pharmacies now prepare it by prescription. This page covers the past and present uses, the evidence, the risks, and how it is regulated.
Information current as of November 10, 2026. Educational only. Confirm everything here with your own clinician before starting, stopping or changing any medication.
At a glance
What it is
A 29 amino acid peptide that matches the active part of growth hormone-releasing hormone (GHRH). It makes the pituitary release growth hormone.
Past FDA use
Geref was approved to diagnose growth hormone deficiency and to treat children with idiopathic growth hormone deficiency.
How it is given
By injection under the skin, according to the prescription. Pharmacies prepare it as a compounded product.
Today
No sermorelin product is marketed in the United States as an approved drug. Compounded sermorelin is not FDA-approved.
Evidence
Best in children with growth hormone deficiency. In healthy adults seeking energy, body composition or sleep benefits, high-quality trials are lacking.
Main cautions
Injection reactions, flushing, headache, and possible effects on blood sugar. Not for active cancer or pregnancy.
Uses
What sermorelin is used for
Sermorelin has two established clinical uses, both from the era when it was a marketed drug. One was a diagnostic test: a dose given by vein, followed by blood tests, to see whether the pituitary can make growth hormone. The other was treatment of prepubertal children with idiopathic growth hormone deficiency, meaning a short child whose body makes too little GH for no clear reason.
Today, adult use is off-label. Doctors who prescribe it in adults usually do so because they suspect low growth hormone activity, because they want to stimulate the pituitary instead of replacing GH, or because the person cannot or would rather not use injectable GH. A confirmed diagnosis of adult growth hormone deficiency is a different matter and calls for endocrine testing first.
Honest framing
Marketing for sermorelin often promises better sleep, leaner bodies and a slower pace of aging. Those claims are not backed by trials I could find. A healthy 45-year-old with normal labs should expect a physician to say so.
How it works
How sermorelin works
The hypothalamus makes GHRH, which tells the pituitary to release growth hormone in pulses, mostly at night. Sermorelin is the first 29 amino acids of that hormone, the shortest piece that keeps full activity. When injected it nudges the pituitary to release GH. The pituitary’s own brakes, including somatostatin and IGF-1 feedback, stay in place.
Because it acts on the pituitary, it only works if the pituitary can respond. It will not help in people whose pituitary has been damaged or removed. Its effect is short, and the body clears it quickly, so how it is timed matters. Your physician explains the schedule on your prescription. This page does not give amounts.
Evidence
What the research shows
A 1999 review of sermorelin in children with idiopathic growth hormone deficiency found that the intravenous test was a rapid and fairly specific way to look for deficiency. In a limited number of children, daily injections at bedtime increased height velocity, and the effect was sustained over 12 months, with some data to 36 months. The review notes that the effect on final adult height was not yet known.
A small multicenter study of 9 children with radiation-induced growth hormone deficiency used GHRH (1-29) twice daily for a year. These were children with a pituitary that still worked, which is the setting where GHRH makes sense.
For adults, I did not find large randomized trials of sermorelin that I could verify for the claims often made online. That does not prove it does nothing. It means the claims go beyond the evidence, so they should be held loosely. Trials in different populations are not directly comparable, and children with GH deficiency are not healthy adults.
Safety
Side effects and cautions
Common effects are redness, pain or itching where the injection goes in, flushing, and headache. Because it raises growth hormone, effects similar to those listed for related drugs are plausible, including swelling, joint aches, and changes in blood sugar. For example, tesamorelin, a related GHRH analog, carries label warnings for fluid retention and glucose intolerance.
Growth hormone is a growth factor. Any growth hormone-raising drug should not be used in people with active cancer, and it needs careful thought if you have a history of cancer. It should not be used in pregnancy. Check your blood sugar and IGF-1 before and during treatment.
Call your physician for
- Swelling in the hands or feet, or numbness and tingling in the hands
- Marked thirst, frequent urination or blurred vision
- A new lump, or a change in an existing mole
- Rash, hives or trouble breathing after an injection
Regulatory status
Where sermorelin stands with pharmacies
Sermorelin was the active ingredient of Geref, which the FDA approved. Geref was later discontinued. In 2013, the FDA published a determination that Geref was not withdrawn from sale for reasons of safety or effectiveness. That means the agency would be able to approve generic versions, if a company applied. No marketed approved sermorelin product exists today.
Sermorelin does not appear on the FDA’s interim lists of nominated bulk substances, which were last updated in May 2026. Pharmacies prepare it as a compounded drug. Compounded sermorelin is not FDA-approved, and the FDA does not evaluate it for safety, effectiveness or quality before it is sold. Because no sermorelin product is currently marketed, the FDA’s rule on compounded copies of marketed drugs does not come into play.
Summit’s role
What Summit does with sermorelin
Dr. Miranda prescribes sermorelin after a physician evaluation. The prescription is prepared by an independent, state-licensed pharmacy for you as a named patient. Your evaluation covers your history, labs, cancer history, blood sugar and what you hope to get from it. Summit does not dispense or sell it, and it keeps no stock in the office.
Nothing on this page promises a prescription. If sermorelin does not fit your history, labs and goals, you will hear why. See pricing for what the program includes, including labs.
Common questions
Questions people ask
Is sermorelin the same as growth hormone?
No. Growth hormone is the hormone itself. Sermorelin signals your pituitary to make its own. Your body’s feedback systems still limit how high it goes.
Is sermorelin FDA-approved?
It was, as Geref, which is no longer marketed. Compounded sermorelin is not FDA-approved, and the FDA does not review compounded drugs for safety, effectiveness or quality.
Will it help me sleep or burn fat?
There is no solid trial evidence for those claims in healthy adults. Results vary, and a physician should tell you so before you decide.
Who should not use it?
People with active cancer, pregnant women, and people whose pituitary does not work. A history of cancer, diabetes or prediabetes needs a careful discussion first.
How is it different from tesamorelin?
Both are GHRH analogs. Tesamorelin is a longer peptide with an FDA-approved product for HIV lipodystrophy. Sermorelin is shorter and has no approved product on the market now.
Sources
Where this comes from
All retrieved November 10, 2026.
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs 1999. https://pubmed.ncbi.nlm.nih.gov/18031173/
- Treatment of radiation-induced growth hormone deficiency with growth hormone-releasing hormone. Clin Endocrinol 1997. https://pubmed.ncbi.nlm.nih.gov/9231053/
- FDA. Determination That GEREF (sermorelin acetate) injection was not withdrawn from sale for reasons of safety or effectiveness. Federal Register, 2013-04827. https://www.federalregister.gov/d/2013-04827
- FDA. Bulk drug substances nominated for use in compounding under section 503A: categories list, updated May 14, 2026. https://www.fda.gov/media/94155/download
Confirm with your provider. This page is general education, not medical advice, and it does not diagnose or treat anything. Every medication carries risks and is not right for everyone. Medication is prescribed only after a physician evaluation determines it is appropriate for you. Individual results vary and no outcome is guaranteed. Information current as of November 10, 2026.
Next step
Start with a physician evaluation
Dr. Miranda reviews your history and labs first, and confirms whether a growth hormone-axis drug makes sense.